Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma

This study is a multicenter, stratified, randomized, active control, double-blinded, parallel-group comparative study with an open-label extension period. The study is designed to evaluate the efficacy and safety of FP/ SLM HFA MDI 50/25 microgram (mcg) one or two inhalation twice daily (BID) for 8 weeks in comparison with FP HFA MDI 50 mcg one or two inhalation BID, in 6-month to 4-year-old Japanese patients with bronchial asthma. The study is also designed to evaluate the safety of long-term treatment of FP/ SLM HFA MDI 50/25 mcg one or two BID for 16 weeks.

The subjects meeting the eligibility criteria will enter the run-in period of 2 weeks and receive FP 50 mcg 1 or 2 inhalation bid (FP 100 or 200 mcg/day), before randomization. The subjects under 2 years of age at Visit 1 will receive only 1 inhalation bid during the run-in period. The subjects who meet the eligibility criteria for randomization will be stratified according to their age (<2 or >=2 year-old) at Visit 1 and randomized to one of the two treatment groups.

The total duration of participation in the study will be 10 weeks for a comparison period completion and 27 weeks for a completion.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Drug: FP/ SLM HFA MDI 50/25 mcg; Drug: FP HFA MDI 50 mcg

• Study Type: Interventional
• Enrollment (Actual): 300
• Phase: Phase 4

Contacts and Locations

Study Locations

• Japan
  • Aichi, Japan, 451-0052
    • GSK Investigational Site
  • Aichi, Japan, 470-1192
    • GSK Investigational Site
  • Chiba, Japan, 260-0001
    • GSK Investigational Site
  • Chiba, Japan, 284-0003
    • GSK Investigational Site
  • Chiba, Japan, 273-0032
    • GSK Investigational Site
  • Ehime, Japan, 790-8524
    • GSK Investigational Site
  • Fukui, Japan, 910-8526
    • GSK Investigational Site
  • Fukui, Japan, 918-8205
    • GSK Investigational Site
  • Fukui, Japan, 910-0833
    • GSK Investigational Site
  • Fukuoka, Japan, 811-1394
    • GSK Investigational Site
  • Fukuoka, Japan, 813-0017
    • GSK Investigational Site
  • Fukuoka, Japan, 802-8533
    • GSK Investigational Site
  • Fukuoka, Japan, 811-3195
    • GSK Investigational Site
  • Fukuoka, Japan, 814-0123
    • GSK Investigational Site
  • Gifu, Japan, 500-8717
    • GSK Investigational Site
  • Gunma, Japan, 372-0817
    • GSK Investigational Site
  • Gunma, Japan, 370-0841
    • GSK Investigational Site
  • Hiroshima, Japan, 720-8520
    • GSK Investigational Site
  • Hiroshima, Japan, 737-0023
    • GSK Investigational Site
  • Hiroshima, Japan, 730-0844
    • GSK Investigational Site
  • Hiroshima, Japan, 730-8518
    • GSK Investigational Site
  • Hiroshima, Japan, 734-0023
    • GSK Investigational Site
  • Hiroshima, Japan, 738-8503
    • GSK Investigational Site
  • Hokkaido, Japan, 070-8530
    • GSK Investigational Site
  • Hokkaido, Japan, 078-8211
    • GSK Investigational Site
  • Hokkaido, Japan, 006-0831
    • GSK Investigational Site
  • Hokkaido, Japan, 064-0821
    • GSK Investigational Site
  • Hokkaido, Japan, 069-0816
    • GSK Investigational Site
  • Hokkaido, Japan, 070-0832
    • GSK Investigational Site
  • Hokkaido, Japan, 078-8811
    • GSK Investigational Site
  • Hyogo, Japan, 650-0047
    • GSK Investigational Site
  • Hyogo, Japan, 653-0021
    • GSK Investigational Site
  • Hyogo, Japan, 674-0068
    • GSK Investigational Site
  • Ibaraki, Japan, 302-0022
    • GSK Investigational Site
  • Ibaraki, Japan, 300-0028
    • GSK Investigational Site
  • Ibaraki, Japan, 312-0057
    • GSK Investigational Site
  • Ishikawa, Japan, 920-8616
    • GSK Investigational Site
  • Kagawa, Japan, 765-0033
    • GSK Investigational Site
  • Kanagawa, Japan, 250-8558
    • GSK Investigational Site
  • Kanagawa, Japan, 231-8682
    • GSK Investigational Site
  • Kanagawa, Japan, 238-8567
    • GSK Investigational Site
  • Kanagawa, Japan, 216-0006
    • GSK Investigational Site
  • Kanagawa, Japan, 221-0014
    • GSK Investigational Site
  • Kanagawa, Japan, 222-0012
    • GSK Investigational Site
  • Kanagawa, Japan, 224-0001
    • GSK Investigational Site
  • Kumamoto, Japan, 861-8520
    • GSK Investigational Site
  • Mie, Japan, 514-0125
    • GSK Investigational Site
  • Miyagi, Japan, 983-0816
    • GSK Investigational Site
  • Okayama, Japan, 700-8607
    • GSK Investigational Site
  • Osaka, Japan, 583-8588
    • GSK Investigational Site
  • Osaka, Japan, 556-0005
    • GSK Investigational Site
  • Osaka, Japan, 565-0862
    • GSK Investigational Site
  • Saga, Japan, 840-8571
    • GSK Investigational Site
  • Saitama, Japan, 351-0102
    • GSK Investigational Site
  • Saitama, Japan, 344-0011
    • GSK Investigational Site
  • Saitama, Japan, 360-0018
    • GSK Investigational Site
  • Saitama, Japan, 360-0812
    • GSK Investigational Site
  • Tochigi, Japan, 321-0293
    • GSK Investigational Site
  • Tokyo, Japan, 196-0003
    • GSK Investigational Site
  • Tokyo, Japan, 190-0023
    • GSK Investigational Site
  • Tokyo, Japan, 154-0017
    • GSK Investigational Site
  • Tokyo, Japan, 157-0066
    • GSK Investigational Site
  • Tokyo, Japan, 176-0012
    • GSK Investigational Site
  • Tokyo, Japan, 158-0094
    • GSK Investigational Site
  • Tokyo, Japan, 154-0002
    • GSK Investigational Site
  • Tokyo, Japan, 152-0021
    • GSK Investigational Site
  • Tokyo, Japan, 173-0015
    • GSK Investigational Site
  • Tokyo, Japan, 202-0004
    • GSK Investigational Site
  • Wakayama, Japan, 646-8558
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 4 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The written informed consent must be obtained from his/her parent or legally acceptable representative. If the investigator can get the oral consent from the patient, the investigator should record so in the informed consent which is signed by his/her parent or legally acceptable representative.
• Ethnic origin is Japanese
• Aged >=6 months and <=4 years at Visit 1.
• Male and pre-menarchial female. Pre-menarchial females are defined as any female who has yet to begin menses.
• Patient: outpatient
• Diagnosis as a pediatric asthma has been made by reference to JPGL 2012 and the document which is of help as evidence should be kept as source document. As for <2 years old, children are going to be diagnosed according to an instruction as follows in JPGL2012 as a reference. There are 3 or more episodes of marked expiratory wheezing, regardless of the presence of respiratory tract infection. It is also needed to confirm that there is asymptomatic period for about a week between each episode. In addition to this finding, if there is at least one of following findings, it is more helpful to diagnose infantile asthma: At least one of parents is diagnosed with bronchial asthma by a physician (including past history); Specific immunoglobulin E (IgE) antibody for inhalation antigen is detected in at least one of parents; Diseased child is diagnosed with atopic dermatitis by a physician (including past history); Specific IgE antibody for inhalation antigen is detected in diseased child; High serum IgE level in diseased child or his/her family (serum IgE level should be determined by considering age); Eosinophils and creola bodies found in sputum (examine nasal discharge eosinophilia and peripheral blood eosinophilia); Expiratory wheezing occurs when there is no airway infection; Expiratory wheezing and labored respiration or oxygen saturation are improved after beta-2 stimulant inhalation.
• A patient who needs to be treated with Inhaled corticosteroid (ICS)/ Long-acting beta 2 agonist (LABA) and fulfill following all conditions: At least one documented exacerbation in that the patient treated with systemic glucocorticosteroids, aminophylline dose intravenous(d.i.v) or continuous isoproterenol inhalation in the 12 months prior to Visit 1. Or a well-documented regular treatment with ICS (FP 200-400 mcg daily or equivalent) continuous use in the 12 months prior to Visit 1; The patient has not received systemic glucocorticosteroids, aminophylline d.i.v., ICS (FP>200 mcg daily or equivalent) or continuous isoproterenol inhalation within 4 weeks prior to Visit 1.

Exclusion Criteria:

• A patient who has suffered from upper and lower respiratory tract infection and then received medication within 2 weeks prior to Visit 1.
• A patient who is diagnosed upper and lower respiratory tract infection at Visit 1. Or a patient who has or is suspected to have deep-seated mycosis or infection to which no effective antibacterial agent is available. Or a patient who is suspected to have respiratory syncytial (RS) virus infection and cannot be identified to be negative for RS virus antigen.
• A patient who has respiratory disorder other than bronchial asthma, and the investigator judges the respiratory disorder affect the assessment of efficacy in this study.
• A patient who has unstable liver disease or chronic stable hepatitis B receiving significant immunosuppressive agents due to risk of hepatitis B reactivation.
• A patient who has malformation/foreign particle lodged in an airway. Or subjects who have known, pre-existing, clinically significant gastroesophageal reflux disease , endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment.
• A patient who has or is suspected to have hypersensitivity to study medications, the rescue medication or any ingredients of them.
• A patient who has been treated with another investigational product within 1 months prior to Visit 1 or within five half-lives (t-half) of the prior investigational study (whichever is the longer of the two).
• As for the patients who has evaluable ECG data at Visit 1, QT interval corrected (Fridericia) for heart rate (QTc[F])>=450 milliseconds (msec). The QT interval corrected for heart rate (QTc) should be based on averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period. As for the patients who don't has evaluable ECG data at Visit 1, if the patient has known prolonged QTc>=450 msec (any correction is valid), the patient will be excluded.
• A patient who is child in care (including foster parent system), or whom the investigator judges inappropriate for the study.

Randomization Inclusion Criterion :

• A patient who has asthma symptoms scores (total of daytime and night-time) both over >=6 in total and >=1 per day for >=3 days at the last 7 consecutive days of the run-in period (excluding the day of Visit 2). Completion of symptom scores (daytime and night-time) on 5 or more days out of the last 7 consecutive days during the run-in period is required.

Randomization Exclusion Criteria :

• A patient who has received systemic steroids during run-in period.
• A patient who has suffered from or is suspected to have upper and lower respiratory tract infection that may affect the assessment of the efficacy during the run-in period. Or a patient who has or is suspected to have deep-seated mycosis or infection to which no effective antibacterial agent is available during the run-in period. Or a patient who is suspected to have RS virus infection and cannot be identified to be negative for RS virus antigen during run-in period.
• A patient who has no evaluable ECG data during the run-in period. As for the patients who has evaluable ECG data during the run-in period, QTc(F) >=450 msec. The QTc should be based on averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period.
• A patient who has not been able to appropriately record patient diary or inhale FP appropriately during the run-in period, in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM); Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.	Drug: FP/ SLM HFA MDI 50/25 mcg; Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
Active Comparator: Fluticasone propionate (FP); Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.	Drug: FP/ SLM HFA MDI 50/25 mcg; Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation; Drug: FP HFA MDI 50 mcg; Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at the End of the Treatment Period 1 (TP1)	The participant's parent or legally acceptable representative made entries asthma symptom experienced by the participant in a patient diary twice daily (day time and night time) in the form of scores on a 4-point rating scale from Baseline (Week -1) until end of TP1 (Week 8). Scores ranged from 0 to 3(0: one, 1: mild, 2: moderate, 3: severe) and maximum score is 6 per day. The Baseline value is a mean value of the last 7 consecutive days during the run-in period (excluding the day of Visit 2 [Randomization]). The end of the TP1 value is a mean value of the last 7 consecutive days during the TP1 (excluding the last day of the TP1). Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 and completed their diary were analyzed.	Baseline and Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change From Baseline in Night-time Asthma Symptoms Score at the End of Treatment Period 1 (TP1)	The participant's parent or legally acceptable representative recorded asthma symptoms experienced by the participant during the night in a patient diary in the form of scores on a 4-point rating scale from Baseline (Week -1) until end of TP1 (Week 8). Scores ranged from 0 to 3(0: one, 1: mild, 2: moderate, 3: severe) and maximum score is 3 per day. Change from Baseline in the asthma symptom scores at night time at the end of TP1 was analyzed. The Baseline value is a mean value of the last 7 consecutive days during the run-in period (excluding the day of Visit 2 [Randomization]). The end of the TP1 value is a mean value of the last 7 consecutive days during the TP1 (excluding the last day of the TP1). Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 and completed their diary were analyzed.	Baseline and Week 8
Mean Change From Baseline in Daytime Asthma Symptoms Score at the End of Treatment Period 1 (TP1)	The participant's parent or legally acceptable representative recorded asthma symptoms experienced by the participant during the day in a patient diary in the form of scores on a 4-point rating scale from Baseline (Week -1) until end of TP1 (Week 8). Scores ranged from 0 to 3(0: one, 1: mild, 2: moderate, 3: severe) and maximum score is 3 per day. Change from Baseline in the asthma symptom scores at day time at the end of TP1 was analyzed. The Baseline value is a mean value of the last 7 consecutive days during the run-in period (excluding the day of Visit 2 [Randomization]). The end of the TP1 value is a mean value of the last 7 consecutive days during the TP1 (excluding the last day of the TP1). Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 and completed their diary were analyzed.	Baseline and Week 8
Number of Participants With at Least One Asthma Exacerbation in Treatment Period 1 (TP1)	The definition of exacerbations was amended during the study. <Original> An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (oral, parenteral, or depot) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. <Amendment> An asthma exacerbation is defined as deterioration of asthma requiring the use of prednisone or hydrocortisone equivalent systemic corticosteroids for at least 3 days, or requiring the use of dexamethasone or betametasone equivalent systemic corticosteroids (oral, intravenous or intramuscular), or requiring the use of systemic depot corticosteroids once, or an in-patient hospitalization that required treatment for respiratory symptom with wheezing, or emergency department visit due to asthma that required intravenous systemic corticosteroids.	Up to 8 weeks
Mean Change From Baseline in Japanese Pediatric Asthma Control Program (JPAC) Score at the End of Treatment Period 1 (TP1)	Severity and control statuses based on Japanese pediatric guideline for the treatment and management of asthma (JPGL) can be assessed according to JPAC. Theoretically range of JPAC score was 0 (poor control) to 18 (complete control) point. JPAC questionnaire was recorded at Baseline (Week -2) and Week 8 by the participant's parent or legally acceptable representative who knew the participant's asthma for the last month. Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 were analyzed.	Baseline and Week 8
Mean Change From Baseline in Use of Rescue Medication (Number of Occasions Used During a 24-hour Period) in Treatment Period 1 (TP1)	The number of inhalations of rescue salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participant's parent or legally acceptable representative twice daily in a patient diary from Baseline (Week -1) until Week 8. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 8 weeks in TP1 were assessed. The Baseline value was derived from the last 7 days of the patient diary prior to the randomization of the participant. Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 and completed their diary were analyzed.	Baseline and Week 8
Mean Change From Baseline in Use of Rescue Medication (Percentage of Days With Rescue-free 24-hour Period) at the End of Treatment Period 1 (TP1)	The number of inhalations of rescue salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participant's parent or legally acceptable representative twice daily in a patient diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 8-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the patient diary prior to the randomization of the participant. Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who completed TP1 and completed their diary were analyzed.	Baseline and Week 8
Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at the End of the Treatment Period 2 (TP2)	The participant's parent or legally acceptable representative recorded asthma symptoms experienced by the participant in a patient diary twice daily (daytime and night time) in the form of scores on a 4-point rating scale from Baseline (Week -1) until end of TP2 (Week 24). Scores ranged from 0 (none) to 3 (severe) and maximum score is 6 per day. Change from Baseline in the asthma symptom scores at daytime plus night time at the end of TP2 was analyzed. The Baseline value is a mean value of the last 7 consecutive days during the run-in period (excluding the day of Visit 2 [Randomization]).The end of the TP2 value is a mean value of the last 7 consecutive days during the TP2 (excluding the last day of the TP2). Change from Baseline is the difference between the value of the endpoint at the time point of interest and the Baseline value. Participants who received at least one dose of open-label medication in the TP2 were analyzed.	Baseline and Week 24

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Yoshihara S, Tsubaki T, Ikeda M, Lenney W, Tomiak R, Hattori T, Hashimoto K, Soutome T, Kato S. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatr Allergy Immunol. 2019 Mar;30(2):195-203. doi: 10.1111/pai.13010. Epub 2019 Feb 6.

Study record dates

Study Major Dates

• Study Start: May 1, 2014
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): October 1, 2016

Study Registration Dates

• First Submitted: March 27, 2014
• First Submitted That Met QC Criteria: April 10, 2014
• First Posted (Estimate): April 14, 2014

Study Record Updates

• Last Update Posted (Actual): June 16, 2017
• Last Update Submitted That Met QC Criteria: March 28, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: Safety; Asthma; Efficacy; Infant; FP/SLM
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma
• Other Study ID Numbers: 200860